F. André reports on study results presented on breast cancer at ASCO 2019. He reports on the clinically significant results from the MONALEESA-7 trial, on results from the SOPHIA trial that tested a new antibody in patients with HER2-positive disease who present with genetic polymorphisms, and results from the NALA trial with interesting data in terms of delaying and preventing brain relapse.
- LBA 1008 / Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2-
- Abstract 1000 / SOPHIA primary analysis
- Abstract 1002 / phase III NALA trial.